Overview
Xellia Pharmaceuticals, founded in 1903 and headquartered in Copenhagen, Denmark, serves as a supplier of anti-infective drugs, encompassing active pharmaceutical ingredients and injectable products to combat serious and life-threatening infections.
The company specializes in developing pharmaceutical ingredients for treating bacterial and fungal infections, including antibiotic-resistant strains. Since 2013, it has been wholly acquired by Novo Holdings A/S. With a global presence, Xellia operates four state-of-the-art manufacturing facilities in Denmark, Hungary, China, and the United States.
Profile
| Country | Denmark |
|---|---|
| Address | Dalslandsgade 11, Copenhagen, Denmark |
| Company Type | Distributor |
| Website | Xellia Pharmaceuticals ApS Website |
Products
1 Xellia Pharmaceuticals ApS's product is listed.